00:00Ladies and gentlemen, please welcome Julien Paillain, co-founder and CEO of Lattice Medical.
00:11Hello, Julien.
00:17Well, hello everyone, ladies and gentlemen, it's a pleasure to be here today.
00:22Hope you enjoy a good session in VivaTech today.
00:25So I'm the CEO and co-founder of Lattice Medical.
00:29We are a medtech company essentially working in the field of breast cancer.
00:34You may know that one woman on eight, unfortunately, will be touched by the breast cancer.
00:40And we perform around 650,000 mastectomies every year to cure the cancer.
00:47And this mastectomy needs a breast reconstruction.
00:52And we have almost 30% of women who have the breast reconstruction.
00:58We have two different techniques to reconstruct the breast.
01:01The first one is the breast implant, mostly made of silicone.
01:07On the right, bottom right, you have a rupture, a collapse of a silicone device.
01:13From the French health authorities, 30% of silicone implants collapsed before five years.
01:20And on the left, you have the risk of a capsule.
01:24It's a fibrotic tissue surrounding the device.
01:27And for both cases, you need to remove the breast device.
01:33And every 10 years, this breast implant needs to be removed to replace it.
01:39So you need several surgeries.
01:43Plastic surgeons have developed autologous surgeries without any device.
01:48But it's a real complex surgery.
01:51You need to harvest a lot of tissue, fat tissue on your back, like this.
01:56And you have a scar of around 25 centimeters.
02:01And it's an impact about the donor site, about the sensibility.
02:06And the surgery takes four hours.
02:09So this is where we are.
02:11We try to tackle these two challenges by offering a new way of breast reconstruction
02:16by taking advantages of both techniques.
02:20And our solution is Matisse.
02:23So Matisse is a breast medical device, a tissue engineering chamber.
02:28We operate like a breast implant.
02:31So the surgeon opens in the mammary fold.
02:34And the surgeon will harvest a small quantity of tissue, fat tissue, just here,
02:40in the intercostal area.
02:43The surgeon raises that tissue.
02:45And the tissue will be inserted inside the Matisse device.
02:50So it's empty inside.
02:52You have the bottom layer.
02:54It's called the scaffold.
02:55We put the tissue on that.
02:57And then we close with the chamber.
03:00We have 21 different sizes.
03:03It's 3D printed.
03:04And it's made of a resorbable material.
03:08So the device is resorbable.
03:11We fix the device on the chest.
03:15And during six months, the device will help the tissue to regenerate inside,
03:21feeling slowly the inner part.
03:23And in the meantime, the device resorbs,
03:26leaving a woman with her own tissue without any long-term material.
03:31So Matisse brings three features.
03:34The regeneration of your own tissue.
03:36A degradable implant.
03:38And it's only a one-hour procedure instead of four hours.
03:45We have done the first clinical trial in France and Spain,
03:49involving several patients in the study.
03:52You can see on this MRI, done seven days after the surgery.
03:58In red, you have the Matisse device.
04:01In green, this is the tissue harvested at the beginning.
04:06And only three months after, the tissue fill in the inner space.
04:13Without any pain, we have a normal wound dealing process.
04:19And we confirm the surgery about one hour.
04:22And if we follow longer the patient, after one year and two years,
04:28we can see that the device is resorbed.
04:32After 12 months, we don't have any visualization about the device.
04:37And after two years, the reconstruction is done.
04:40The implant is resorbed and the woman gets back her own breasts.
04:49And on the top of that, we have developed a unique and scalable 3D printing tool in a clean room.
04:56So we do ourselves, the biomaterial and the device.
05:01We have implemented a pilot scale unit with 3D printers.
05:05We have a booth just behind here.
05:08And you can see a printer doing a Matisse implant.
05:11So we generate the biomaterial.
05:15We have any design to produce the shape of the Matisse device.
05:21Then we have some post-processing operation, washing, cleaning.
05:28We have the sterilization process.
05:31And then we have a quality control on any device.
05:34Visual inspection, dimensional, and also with the mass.
05:42This is compliant to the medical quality standards.
05:45We are certified ISO 13485.
05:48And we have a capacity today to produce more than 1,000 implants per year.
06:01So now we are still in the clinical trials.
06:04We will involve more patients next year on a multicentric study in France and Spain.
06:11And we expect to have the C mark in 2028.
06:16And then we will pursue some studies on reimbursements to get a reimbursement code on Matisse.
06:25And in the meantime, we will develop our U.S. roadmap to also get a certification on the U.S.
06:33market, the biggest market in the world.
06:37You have here a view of the team.
06:40We are 25 people mixing engineers, doctors, surgeons, medical doctors in the field of plastic surgery, oncology, gynecology.
06:50The company succeeded in three different routes on fundraising.
06:54And the last one, last year, we raised 43 million euros to expand our clinical trial activity and industrial activity.
07:04And the company has several partnerships in France with a producer of implants and also different providers in software and
07:15research.
07:16And we work with the best key opinion leaders in the field of breast reconstruction and plastic surgery in Europe.
07:25Our business model will be a mix between direct sales and distribution.
07:32The product targets two different indications, the breast reconstruction in cancer and also the aesthetic market with the breast augmentation.
07:41So for the reconstruction, we will commercialize ourselves the product and we will target a reimbursement price on the product.
07:49And for the high aesthetic market, we aim to conclude a licensing agreement with a top-tier company in that
07:56field.
07:57We aim a $2,000 price for Matisse in Europe and $8,000 in the U.S. with the reimbursement
08:05code.
08:05And for the high aesthetic, the price will be fixed around 1,400 euros.
08:13And you have here our revenue forecast since we launched the product in 2028 with the licensing opportunity.
08:22I'd like to thank you for your attention and I think you have one or two minutes for any questions.
08:28Thank you so much.
08:36Yes, you have time for questions.
08:40Perfect.
08:42Yes.
08:43Oh, a lot of questions.
08:45We like that.
08:49I wanted to ask why the price for the aesthetic market is cheaper than the other market.
08:58Because of the benefits of the device and also the market.
09:02You have already a market of breast implants in high aesthetic with a certain fixed price.
09:08And it's normal to be close to that price.
09:12And for the reconstruction, the benefits is higher for women.
09:18So, that's why we explain a higher price for reconstruction.
09:27The 3D printing procedure will be the same?
09:31Everything will be the same?
09:32Just the price will be different?
09:35Or, like, in the first place, you will have something different?
09:41I mean, for more reconstruction, more benefit for the cells because before there was also cancer?
09:49So, the procedure should be almost the same.
09:52But the difference is the size of the implants.
09:54In breast aesthetics, you have already a breast.
09:57So, you put smaller implants.
09:59In breast reconstruction, you lose your whole breast.
10:02So, you need a bigger implant and a bigger amount of fat.
10:04So, the procedure is a bit longer and the device too.
10:11I'd like to congratulate you for trying this.
10:15It's very challenging.
10:16But how do you get through all these regulatory phases?
10:20Because you have to check the material, the consistency.
10:24Will it impact?
10:26Or can it have some challenges?
10:28It's difficult to hear.
10:30Sorry.
10:33What are the challenges by the material itself which you put inside the body?
10:38Will it have some kind of effects?
10:43So, it's a medical device.
10:45It's an implantable device.
10:46So, you need a long follow-up on patient to see any side effects about the reservoir material.
10:53But we have chosen a material which is already used in medical application.
10:59The biomaterial is the same like suture yarn.
11:03And the sutures are used since 40, 50 years from now in the medical area.
11:07So, we are confident about the risk of side effects.
11:15Thank you so much.
11:16Julia Payen, co-founder and CEO of Lattice Medical.
Comments